Testing Data
(Purity assesment by SDS-PAGE0.5 mug of Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade) and cetuximab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Human anti-Human EGF Receptor Monoclonal Antibody | anti-EGFR antibody
Human Anti EGF Receptor (Cetuximab Biosimilar)
Purified IgG prepared by affinity chromatography on Protein A
Purified IgG prepared by affinity chromatography on Protein A
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Should this product contain a precipitate we recommend microcentrifugation before use.
Testing Data
(Purity assesment by SDS-PAGE0.5 mug of Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade) and cetuximab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Purity assesment by SDS-PAGE0.5 mug of Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade) and cetuximab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade) and cetuximab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade) and cetuximab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Testing Data
(Cetuximab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Cetuximab Antibody (clone AbD19834, HCA220) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of cetuximab (therapeutic reference product) or Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Cetuximab Antibody (clone AbD19830_hIgG1, HCA221P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Testing Data
(Cetuximab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Cetuximab Antibody (clone AbD19834, HCA220) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of cetuximab (therapeutic reference product) or Human Anti-EGF R Antibody, MCA6102 (cetuximab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Cetuximab Antibody (clone AbD19830_hIgG1, HCA221P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Summary: Human Anti-EGF R Antibody, clone C225 is a research grade biosimilar of the monoclonal antibody drug cetuximab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic antibody cetuximab.
Human Anti-EGF R Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-cetuximab antibodies, for example HCA220 and HCA221P. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-cetuximab antibody in IgG1 format as reference standard, for example HCA221.
Cetuximab (Erbitux) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody is directed against EGFR and inhibits tumor cell proliferation by blocking the interaction of epidermal growth factor (EGF) with its receptor.
NCBI and Uniprot Product Information
NCBI Description
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jun 2016]
Uniprot Description
EGFR: a receptor tyrosine kinase. This is a receptor for epidermal growth factor (EGF) and related growth factors including TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor. EGFR is involved in the control of cell growth and differentiation. It is a single-pass transmembrane tyrosine kinase. Ligand binding to this receptor results in receptor dimerization, autophosphorylation (in trans), activation of various downstream signaling molecules and lysosomal degradation. It can be phosphorylated and activated by Src. Activated EGFR binds the SH2 domain of phospholipase C-gamma (PLC-gamma), activating PLC-gamma-mediated downstream signaling. Phosphorylated EGFR binds Cbl, leading to its ubiquitination and degradation. Grb2 and SHC bind to phospho-EGFR and are involved in the activation of MAP kinase signaling pathways. Phosphorylation on Ser and Thr residues is thought to represent a mechanism for attenuation of EGFR kinase activity. EGFR is overexpressed in breast, head and neck cancers, correlating with poor survival. Activating somatic mutations are seen in lung cancer, corresponding to the minority of patients with strong responses to the EGFR inhibitor Iressa (gefitinib). Mutations and amplifications are also seen in glioblastoma, and upregulation is seen in colon cancer and neoplasms. In xenografts, inhibitors synergize with cytotoxic drugs in the inhibition of many tumor types. Inhibitors include: Iressa/ZD1839, Erbitux, Tarceva, and lapatinib. Four alternatively spliced isoforms have been described.
Protein type: Kinase, protein; Tumor suppressor; EC 2.7.10.1; Protein kinase, tyrosine (receptor); Protein kinase, TK; Membrane protein, integral; TK group; EGFR family
Chromosomal Location of Human Ortholog: 7p12
Cellular Component: extracellular space; endoplasmic reticulum membrane; nuclear membrane; cell surface; focal adhesion; basolateral plasma membrane; integral to membrane; lipid raft; Golgi membrane; membrane; perinuclear region of cytoplasm; apical plasma membrane; cytoplasm; plasma membrane; AP-2 adaptor complex; endosome membrane; nucleus; endosome; receptor complex
Molecular Function: identical protein binding; epidermal growth factor receptor activity; epidermal growth factor binding; nitric-oxide synthase regulator activity; transmembrane receptor protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; protein phosphatase binding; protein kinase binding; integrin binding; actin filament binding; protein binding; enzyme binding; transmembrane receptor activity; MAP kinase kinase kinase activity; protein heterodimerization activity; ubiquitin protein ligase binding; protein-tyrosine kinase activity; double-stranded DNA binding; chromatin binding; glycoprotein binding; ATP binding
Biological Process: circadian rhythm; diterpenoid metabolic process; positive regulation of nitric oxide biosynthetic process; activation of MAPKK activity; nerve growth factor receptor signaling pathway; alkanesulfonate metabolic process; protein insertion into membrane; positive regulation of vasodilation; G1/S-specific positive regulation of cyclin-dependent protein kinase activity; positive regulation of MAP kinase activity; positive regulation of fibroblast proliferation; cell-cell adhesion; cell surface receptor linked signal transduction; ovulation cycle; hair follicle development; positive regulation of superoxide release; negative regulation of mitotic cell cycle; positive regulation of DNA repair; fibroblast growth factor receptor signaling pathway; digestive tract morphogenesis; response to osmotic stress; phospholipase C activation; response to hydroxyisoflavone; hydrogen peroxide metabolic process; positive regulation of transcription from RNA polymerase II promoter; response to oxidative stress; regulation of nitric-oxide synthase activity; response to calcium ion; negative regulation of protein catabolic process; positive regulation of epithelial cell proliferation; negative regulation of apoptosis; negative regulation of epidermal growth factor receptor signaling pathway; tongue development; axon guidance; embryonic placenta development; peptidyl-tyrosine phosphorylation; translation; protein amino acid autophosphorylation; positive regulation of smooth muscle cell proliferation; signal transduction; positive regulation of synaptic transmission, glutamatergic; learning and/or memory; salivary gland morphogenesis; positive regulation of cell proliferation; response to stress; regulation of peptidyl-tyrosine phosphorylation; epidermal growth factor receptor signaling pathway; ossification; phosphoinositide-mediated signaling; MAPKKK cascade; liver development; positive regulation of protein kinase B signaling cascade; cell proliferation; cerebral cortex cell migration; calcium-dependent phospholipase A2 activation; positive regulation of vasoconstriction; innate immune response; positive regulation of protein amino acid phosphorylation; astrocyte activation; response to cobalamin; positive regulation of phosphorylation; positive regulation of DNA replication; positive regulation of inflammatory response; lung development; positive regulation of cell migration
Disease: Lung Cancer
Research Articles on EGFR
Similar Products
Product Notes
The EGFR egfr (Catalog #AAA225703) is an Antibody produced from Human and is intended for research purposes only. The product is available for immediate purchase. The Human Anti EGF Receptor (Cetuximab Biosimilar) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's EGF Receptor can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Researchers should empirically determine the suitability of the EGFR egfr for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "EGF Receptor, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
